<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407366</url>
  </required_header>
  <id_info>
    <org_study_id>FGSLC-2015</org_study_id>
    <nct_id>NCT02407366</nct_id>
  </id_info>
  <brief_title>Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase 2 Study of Icotinib With Concurrent Radiotherapy vs. Pemetrexed+ Carboplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor ( EGFR) Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>People's Hospital of Guangxi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard of care for unresectable locally advanced non-small-cell lung cancer
      (NSCLC) is a combination of chemotherapy and thoracic radiotherapy (TRT). The standard
      regimens consist of platinum-based doublet chemotherapy.Icotinib(BPI-2009, Conmana) is the
      first self-developed small molecular drug in China for targeted therapy of lung
      cancer.Icotinib is a novel oral quinazoline compound that has proven survival benefit in
      Chinese patients with lung cancer,especially in EGFR mutation lung cancer. This randomised,
      multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with
      concurrent radiotherapy versus pemetrexed + carboplatin with concurrent radiotherapy in
      inoperable stage III non-small cell lung cancer with EGFR mutation, the primary endpoint is
      progression-free survival.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>One year</time_frame>
    <description>A duration from randomization date to disease progression(as defined by RECIST) or death. If a participant are known to have progressed, the time to progression is defined as the time from the date of randomization to the date of progression. Otherwise, a participant will be censored at the last date they are known not to be progressed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>two years</time_frame>
    <description>Overall survival is assessed via calculation of the time to death due to any cause. If a participant is known to have died, the time to death is defined as the time from the date of randomization to the date of death. Otherwise, a participant will be censored at the last date they are known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>two years</time_frame>
    <description>The number of patients who suffered adverse events, which is graded by NCI CTCAE version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>two years</time_frame>
    <description>Number of subjects with confirmed objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>two years</time_frame>
    <description>Quality of life as measured by the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Icotinib with concurrent radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Icotinib (125 mg ,three times daily)with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by maintenance icotinib (125 mg ,Three times daily) until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days for three cycles with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by consolidation chemotherapy with two cycles of pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days.Maintenance pemetrexed(500mg/m2) will be administered after consolidation chemotherapy until disease progression or unacceptable toxicity .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>Icotinib (125 mg ,Three times daily)</description>
    <arm_group_label>Icotinib with concurrent radiotherapy</arm_group_label>
    <other_name>BPI-2009</other_name>
    <other_name>Conmana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed(500mg/m2)every 21 days</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <other_name>Alimta</other_name>
    <other_name>LY231514</other_name>
    <other_name>MTA</other_name>
    <other_name>Multitargeted Antifolate</other_name>
    <other_name>NSC-698037</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin (AUC，5) every 21 days</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic radiotherapy(TRT)</intervention_name>
    <description>TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)</description>
    <arm_group_label>Icotinib with concurrent radiotherapy</arm_group_label>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unresectable stage IIIA / IIIB non-small cell lung cancer with EGFR 19/21 mutation.

          2. No previous systemic anticancer therapy.

          3. life expectancy more than three months.

          4. ECOG Performance Status of 0 to 1.

          5. Measurable lesion according to RECIST with at least one measurable lesion not
             previously irradiated, unless disease progression has been documented at that site.

          6. Patients will be required to provide informed consent before enrollment.

        Exclusion Criteria:

          1. Intrapulmonary metastasis, atelectasis of an entire hemithorax,pleural dissemination,
             or contralateral hilar lymph node metastasis.

          2. Prior chemotherapy for NSCLC, chest irradiation therapy, or therapy directed at the
             epidermal growth factor receptor pathway.

          3. Severe heart disease, uncontrolled diabetes mellitus, or active infection.

          4. Active concomitant malignancy, and pregnancy or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GuoSheng Feng, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The People's hospital of Guangxi Zhuang Autonomous</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuan Liang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Guangxi Department of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Hui, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The People's hospital of Guangxi Zhuang Autonomous</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HeMing Lu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The People's hospital of Guangxi Zhuang Autonomous</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ChangJie Huang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanning Second People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GuiSheng LI, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Liuzhou Worker's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HaiXin Huang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Liuzhou Worker's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HaoLin Yan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>First People's Hospital of Yulin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ping Liang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Guangxi Ruikang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BingQiang Ni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The People's hospital of LiuZhou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>YanRong Hao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The People's hospital of Guangxi Zhuang Autonomous</affiliation>
  </overall_official>
  <overall_official>
    <last_name>XianBin Yuan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The People's hospital of Guangxi Zhuang Autonomous</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shan Gao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The People's hospital of Guangxi Zhuang Autonomous</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xia Wu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The People's hospital of Guangxi Zhuang Autonomous</affiliation>
  </overall_official>
  <overall_official>
    <last_name>XiangLi Lai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The People's hospital of Guangxi Zhuang Autonomous</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xia Wu, intern</last_name>
    <phone>+86-185-789-52759</phone>
    <email>353992578@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>XiangLi Lai, intern</last_name>
    <phone>+86-138-7719-7891</phone>
    <email>249261276@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The people's Hospital of the Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GuoSheng Feng, professor</last_name>
      <phone>+86-771-218-6508</phone>
      <email>fengguosheng88988@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>People's Hospital of Guangxi</investigator_affiliation>
    <investigator_full_name>Guosheng Feng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Inoperable stage III non-small cell lung cancer</keyword>
  <keyword>EGFR mutation</keyword>
  <keyword>Icotinib</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

